Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

@article{Amass2004BringingBD,
  title={Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.},
  author={Leslie Amass and W Emily Ling and Thomas E Freese and Chris Reiber and Jeffrey J. Annon and Allan J. Cohen and Dennis McCarty and Malcolm S. Reid and Lawrence S Brown and Cynthia Clark and Douglas M. Ziedonis and Jonathan Krejci and Susan M. Stine and Theresa M. Winhusen and Greg S Brigham and Dean L Babcock and Joan A Muir and Betty J Buchan and Terry L Horton},
  journal={The American journal on addictions},
  year={2004},
  volume={13 Suppl 1},
  pages={S42-66}
}
In October 2002, the U.S. Food and Drug Administration approved buprenorphine-naloxone (Suboxone) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for Clinical Trials Network (CTN) sponsored two clinical trials assessing buprenorphine-naloxone for short-term opioid detoxification. These trials provided an unprecedented field test of its use in twelve diverse community-based treatment programs. Opioid… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
55 Extracted Citations
91 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 55 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 91 references

Similar Papers

Loading similar papers…